The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The discovery that AD could be inherited in an autosomal dominant fashio”
Background
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Items 801–900 of 1,007
Montoliu‐Gaya, L., Mulder, S. D., Herrebout, M. A. C., Baayen, J. C., Villegas, S., & Veerhuis, R. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.03.015 · Cited by 34
“Patients with familial early-onset AD (EOAD) either carry mutations in the Aβ region of the amyloid precursor protein (APP), or in other genes related with Aβ processing (PSEN1, PSEN2) (Benilova et al., 2012; Karran et al., 2011), which suggests that Aβ plays a key role in AD pathogenesis, as exemplified by subsequent…”
Song, S., Lee, J. U., Jeon, M. J., Kim, S., Lee, C.-N., & Sim, S. J. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115269 · Cited by 34
Kulichikhin, K. Y., Fedotov, S. A., Rubel, M. S., Zalutskaya, N. M., Zobnina, A. E., Malikova, O. A., Незнанов, Н. Г., Chernoff, Y. O., & Rubel, A. A. (2021) · Prion · doi:10.1080/19336896.2021.1917289 · Cited by 35
“According to amyloid cascade hypothesis, the deposition of the Aβ peptide and tau protein in the brain are central events in AD pathology [44], and this concept is accepted by NIA and AA in their definition of AD [3,4] mentioned above.”
BackgroundZhao, H., Liu, J., Wang, Y., Shao, M., Wang, L., Tang, W., Wang, Y., & Li, X. (2023) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.12673 · Cited by 38
Lowerison, M. R., Sekaran, N. V. C., Dong, Z., Chen, X., You, Q., Llano, D. A., & Song, P. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1251-23.2024 · Cited by 55
“The current hallmarks of AD are amyloid beta (A β ) deposition and abnormal accumulations of neuro fi brillary tau protein (Bloom, 2014), motivating substantial research e ff ort centered on the amyloid hypothesis (Glenner and Wong, 1984; Hardy and Allsop, 1991; Karran et al., 2011) of AD.”
BackgroundMesenchymal Stem Cell-Derived Exosomes as a Neuroregeneration Treatment for Alzheimer’s Disease
Shah, S., Mansour, H. M., Aguilar, T. M., & Lucke-Wold, B. P. (2024) · Biomedicines · doi:10.3390/biomedicines12092113 · Cited by 41
“Additionally, these drugs may have poor outcomes and side effects in elderly patients such as syncope and reduced cardiac output that further call for the importance of developing new therapeutic approaches [15].”
BackgroundWhy therapies for Alzheimer’s disease do not work: Do we have consensus over the path to follow?
Amtul, Z. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.09.003 · Cited by 39
Elevated amyloid-β plaque deposition in dietary selenium-deficient Tg2576 transgenic mice
Haratake, M., Yoshida, S., Mandai, M., Fuchigami, T., & Nakayama, M. (2013) · Metallomics · doi:10.1039/c3mt00035d · Cited by 33
TL-2 attenuates β-amyloid induced neuronal apoptosis through the AKT/GSK-3β/β-catenin pathway
Zhu, X., Wang, S., Yu, L., Yang, H., Tan, R. X., Yin, K., Jin, J., Zhao, H., Guan, D., & Xu, Y. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000315 · Cited by 33
“…does not prevent the progressive neurodegeneration in patients with AD (Holmes et al., 2008), it is generally considered that accumulation of Aβ is the key event in AD pathology and contributes to neuronal cell death and the formation of NFTs (Karran et al., 2011; Honjo et al., 2012; Reitz, 2012).”
InfluentialCholesterol Drives Aβ(1–42) Interaction with Lipid Rafts in Model Membranes
Seghezza, S., Diaspro, A., Canale, C., & Dante, S. (2014) · Langmuir · doi:10.1021/la502966m · Cited by 33
Liang, J., Kulasiri, D., & Samarasinghe, S. (2015) · Biosystems · doi:10.1016/j.biosystems.2015.05.003 · Cited by 34
“…proposed and attempted to explain the causes of AD, such as the amyloid deposition hypothesis (Hardy and Higgins, 1992; Hardy and Selkoe, 2002a; Karran et al., 2011), the tau hypothesis (Braak and Braak, 1991; Iqbal et al., 2005; Wischik et al., 2010) and the cholinergic hypothesis (Bartus et…”
BackgroundAmyloid-β containing isoaspartate 7 as potential biomarker and drug target in Alzheimer's disease
Kozin, S. A., Mitkevich, V. A., & Makarov, A. А. (2016) · Mendeleev Communications · doi:10.1016/j.mencom.2016.07.001 · Cited by 34
Nanomedicine against Aβ Aggregation by β–Sheet Breaker Peptide Delivery: In Vitro Evidence
Pederzoli, F., Ruozi, B., Duskey, J. T., Hagmeyer, S., Sauer, A. K., Grabrucker, S., Coelho, R., Oddone, N., Ottonelli, I., Daini, E., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110572 · Cited by 37
“The progressive accumulation of Aβ aggregates is widely believed to be fundamental to the initial development of the neurodegenerative pathology and to trigger neurotoxicity, oxidative damage, and inflammation that contribute to the progression of AD [1].”
BackgroundBen-Nejma, I. R. H., Keliris, A., Daans, J., Ponsaerts, P., Verhoye, M., der Linden, A. V., & Keliris, G. A. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0810-7 · Cited by 36
Discovery and development of ASK1 inhibitors
Brys, R., Gibson, K. R., Poljak, T., der Plas, S. E. V., & Amantini, D. (2020) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2020.02.001 · Cited by 33
Yussof, A., Yoon, P., Krkljes, C., Schweinberg, S., Cottrell, J., Chu, T., & Chang, S. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-76784-x · Cited by 33
Pavlidis, N., Kofinas, A., Papanikolaou, M. G., Miras, H. N., Drouza, C., Kalampounias, A. G., Kabanos, T. A., Konstandi, M., & Leondaritis, G. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111393 · Cited by 35
“It is characterized by episodic memory loss and decline of various mental functions including cognitive ability, spatial orientation, attention and speech ability [2,3].”
Amyloids: The History of Toxicity and Functionality
Yakupova, E. I., Bobyleva, L. G., Shumeyko, S. A., Vikhlyantsev, I. M., & Bobylev, A. G. (2021) · Biology · doi:10.3390/biology10050394 · Cited by 39
Kalweit, A. N., Yang, H., Colitti-Klausnitzer, J., Fülöp, L., BozsÃ, Z., Penke, B., & Manahan‐Vaughan, D. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00103 · Cited by 41
“…cascade hypothesis postulates that amyloid-beta (Aβ)-deposition is triggered mainly by Aβ(1–42) and that this aberrant aggregation behavior leads to neuronal death (Lambert et al., 1998; Barghorn et al., 2005; Karran et al., 2011) and cognitive dysfunction (Cleary et al., 2005; Geng et al., 2010).”
BackgroundLeirós, M., Alonso, E., Rateb, M. E., Ebel, R., Jaspars, M., Alfonso, A., & Botana, L. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.082 · Cited by 36
Kaur, K., Kulkarni, Y. A., & Wairkar, S. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148905 · Cited by 38
Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 38
“What is the relationship between the extent of Aβ lowering required for efficacy and disease stage? For example, does it escalate with disease progression - that is, is the requirement for Aβ reduction lower if intervention is earlier (predementia/presymptomatic), and greater if intervention is later in disease (mild…”
BackgroundPrion-like Mechanisms in Alzheimer's Disease
Yin, R., Tan, L., Jiang, T., & Yu, J. (2014) · Current Alzheimer Research · doi:10.2174/156720501108140910121425 · Cited by 37
Targeting β-Amyloid Plaques and Oligomers: Development of Near-Ir Fluorescence Imaging Probes
Liu, H., Yang, J., Wang, L., Xu, Y., Zhang, S., Lv, J., Ran, C., & Li, Y. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0185 · Cited by 33
Kuznetsov, I. A., & Kuznetsov, A. V. (2018) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2017.0777 · Cited by 37
Wang, X., Kastanenka, K. V., Arbel‐Ornath, M., Commins, C., Kuzuya, A., Lariviere, A., Krafft, G. A., Hefti, F. F., Jerecìć, J., & Bacskai, B. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-22979-2 · Cited by 33
Wnt signalling pathway and tau phosphorylation: A comprehensive study on known connections
Hadi, F., Akrami, H., Shahpasand, K., & Fattahi, M. R. (2020) · Cell Biochemistry and Function · doi:10.1002/cbf.3530 · Cited by 30
Tavanti, F., Pedone, A., & Menziani, M. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155462 · Cited by 34
King‐Robson, J., Initiative, A. D. N., Wilson, H., & Politis, M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201457 · Cited by 31
“While progressive amyloid-(cid:2) deposition has been related to disease progression, the nature of this relationship remains unclear [2, 11, 69].”
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
“This focus has led to exploration in clinical trials of anti-Aβ therapies for AD treatment, which have thus far garnered little success (Karran et al. 2011; Karran and Hardy 2014).”
BackgroundWang, Y., Xiong, B., Lin, H., Li, Q., Yang, H., Qiao, Y., Li, Q., Xu, Z., Lyu, W., Qu, W., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114806 · Cited by 33
Decourt, B., Noorda, K., Noorda, K. J., Shi, J., & Sabbagh, M. N. (2022) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265626 · Cited by 34
“However, evidence supports Aβ’s critical role, as an increased Aβ42/Aβ40 ratio in the cerebrospinal fluid (CSF) predisposes individuals to develop AD.(14) Thus, in addition to the amyloid cascade hypothesis, some authors have formulated an amyloid threshold hypothesis, which proposes that, if Aβ levels are maintained…”
BackgroundResultInfluentialThe link between periodontitis and Alzheimer's disease – emerging clinical evidence
Wu, D. T. S., Cho, Y. W., Spalti, M. D., Bishara, M., & Nguyen, T. T. H. (2022) · Dentistry Review · doi:10.1016/j.dentre.2022.100062 · Cited by 40
Jackson, H. M., Onos, K. D., Pepper, K. W., Graham, L. C., Akeson, E. C., Byers, C., Reinholdt, L. G., Frankel, W. N., & Howell, G. R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125897 · Cited by 32
Animal models of source memory
Crystal, J. D. (2016) · Journal of the Experimental Analysis of Behavior · doi:10.1002/jeab.173 · Cited by 32
Murakami, K., & Irie, K. (2019) · Molecules · doi:10.3390/molecules24112125 · Cited by 31
“Aβ itself is considered a physiological by-product of cellular metabolism because it can be detected as a circulating protein in the cerebrospinal fluid and blood of healthy humans [3]; the physiological function of Aβ is summarized in a recent review by Panza et al.”
BackgroundPharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers
Brazier, D., Perry, R., Keane, J., Barrett, K., & Elmaleh, D. R. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0549-5 · Cited by 31
“This neuro-inflammatory response, besides promoting local vascular leakage through the blood-brain barrier [10], has been implicated in driving further production of aberrant Ab peptides 40/42 via modulation of gamma-secretase activity [11, 12] and to be detrimental to hippocampal neurogenesis in the adult brain [13].”
BackgroundLin, L.-W., Tsai, F.-H., Lan, W.-C., Cheng, Y.-D., Lee, S.-C., & Wu, C.-R. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1436-7 · Cited by 31
Onisiforou, A., Charalambous, E. G., & Zanos, P. (2025) · Microorganisms · doi:10.3390/microorganisms13010090 · Cited by 36
“This leads to an imbalance between A β production and removal, causing the peptides to aggregate and form soluble oligomers, fibrils, and eventually extracellular amyloid plaques, a hallmark of AD [4].”
InfluentialWhitehouse, P. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.017 · Cited by 32
“Here the identification of the genes that affect amyloid processing in early onset, familial AD (EOAD) appeared to suggest that interventions at this level could lead to therapies that might more directly alter the basic pathogenesis and prevent cell death rather than merely improve neurotransmitter function [23].”
BackgroundZiehm, T., Brener, O., van Groen, T., Kadish, I., Frenzel, D., Tusche, M., Kutzsche, J., Reiß, K., Gremer, L., Nagel‐Steger, L., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00047 · Cited by 31
Pathobiology of Neurodegeneration: The Role for Astroglia
Verkhratsky, A., Zorec, R., Rodriguez, J. J., & Parpura, V. (2016) · Opera medica et physiologica · doi:10.20388/omp2016.001.0019 · Cited by 37
Physical principles of filamentous protein self-assembly kinetics
Michaels, T. C. T., Liu, L. X., Meisl, G., & Knowles, T. P. J. (2017) · Journal of Physics Condensed Matter · doi:10.1088/1361-648x/aa5f10 · Cited by 33
Gimeno, A., Santos, L. M., Alemi, M., Rivas, J., Blasi, D., Cotrina, E. Y., Llop, J., Valencia, G., Cardoso, I., Quintana, J. R., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00428 · Cited by 31
Reale, M., Gonzales-Portillo, I., & Borlongan, C. V. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146535 · Cited by 34
Gadhave, K., Gehi, B. R., Kumar, P., Xue, B., Uversky, V. N., & Giri, R. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03414-9 · Cited by 36
Ren, Z., Dong, Z., Xie, P., Lv, J., Hu, Y., Guan, Z.-Z., Zhang, C., & Yu, W. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11132 · Cited by 32
“Pathological characteristics of ad often include neuronal apoptosis, synaptic loss and cognitive impairment, which are considered to be associated with abnormal aggregation of aβ (2,3).”
BackgroundPoor oral health conditions and cognitive decline: Studies in humans and rats
Zhang, S., Yang, F., Wang, Z., Qian, X., Ji, Y., Gong, L., Ge, S., & Yan, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234659 · Cited by 39
“In addition to the amyloid hypothesis [4, 5] and tau protein hypothesis [6, 7], inflammation may also play an important role in the pathogenesis of AD [8] and cognitive decline [9].”
BackgroundRecent advances of small molecule JNK3 inhibitors for Alzheimer’s disease
Qin, P., Ran, Y., Liu, Y., Wei, C., Luan, X., Niu, H., Peng, J., Sun, J., & Wu, J. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106090 · Cited by 33
Dentoni, G., Castro‐Aldrete, L., Naia, L., & Ankarcrona, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.920228 · Cited by 35
“Therefore, by the time cognitive impairment is clinically observed, Aβ accumulation has already plateaued (Hardy and Selkoe, 2002; Jack et al., 2010; Karran et al., 2011; Selkoe and Hardy, 2016).”
BackgroundAlzheimer’s Disease, Astrocytes and Kynurenines
Dézsi, L., Tuka, B., Martos, D., & Vécsei, L. (2015) · Current Alzheimer Research · doi:10.2174/156720501205150526114000 · Cited by 32
Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials
Soejitno, A., Tjan, A., & Purwata, T. E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0257-8 · Cited by 35
“[24] can be considered excellent guidance in addressing this timeframe issue.”
BackgroundPettersson, M., Johnson, D. S., Subramanyam, C., Bales, K. R., Ende, C. W. A., Fish, B. A., Green, M., Kauffman, G. W., Mullins, P. B., Navaratnam, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401782h · Cited by 33
Abnormal Population Responses in the Somatosensory Cortex of Alzheimer’s Disease Model Mice
Maatuf, Y., Stern, E. A., & Slovin, H. (2016) · Scientific Reports · doi:10.1038/srep24560 · Cited by 36
APP Overexpression Causes Aβ-Independent Neuronal Death through Intrinsic Apoptosis Pathway
Cheng, N., Jiao, S., Gumaste, A., Bai, L., & Belluscio, L. (2016) · eNeuro · doi:10.1523/eneuro.0150-16.2016 · Cited by 31
Folate/Vitamin B Alleviates Hyperhomocysteinemia-Induced Alzheimer-Like Pathologies in Rat Retina
Guo, J., Ni, S.-Z., Li, Q., Wang, J., & Yang, Y. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0293-8 · Cited by 31
Systematic reviews of the literature: a better way of addressing basic science controversies
O’Hagan, E. C., Matalon, S., & Riesenberg, L. A. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00544.2017 · Cited by 40
Li, G., Hsu, L., Wu, Y., Bozoki, A., Shih, Y. I., & Yap, P. (2025) · Communications Medicine · doi:10.1038/s43856-025-00736-7 · Cited by 51
Niva, C., PARKINSON, J. R., Olsson, F., van Schaick, E., Lundkvist, J., & Visser, S. A. G. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1459-3 · Cited by 32
“The phase 3 trial with semagacestat was stopped prematurely because of a clear cognitive worsening at the interim analysis [2, 6, 7].”
BackgroundChen, J. J., Liu, Q., Yuan, C., Gore, V., Lopez, P., Ma, V., Amegadzie, A. K., Qian, W., Judd, T. C., Minatti, A., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.092 · Cited by 30
Intracellular FRET-based Screen for Redesigning the Specificity of Secreted Proteases
Guerrero, J. L., O’Malley, M., & Daugherty, P. S. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01051 · Cited by 29
A Cyclic Peptide Mimic of the β-Amyloid Binding Domain on Transthyretin
Cho, P. Y., Gururaj Joshi, A., Boersma, M., Johnson, J. A., & Murphy, R. M. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn500272a · Cited by 30
Amyloid Plaques in Retina for Diagnosis in Alzheimer’s Patients: a Meta-Analysis
Jiang, J., Wang, H., Li, W., Cao, X., & Li, C. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00267 · Cited by 32
“According to the Aβcascade hypothesis, the principal event in the pathogenesis of AD is the accumulation of Aβ plaques in the brain (Hardy and Selkoe, 2002; Jack et al., 2010; Karran et al., 2011).”
BackgroundInfluentialAminyavari, S., Zahmatkesh, M., Khodagholi, F., & Sanati, M. (2019) · Peptides · doi:10.1016/j.peptides.2019.170102 · Cited by 30
Zolochevska, O., & Taglialatela, G. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01868-8 · Cited by 30
Wu, J., Qu, J.-Q., Zhou, Y., Zhou, Y., Li, Y., Huang, N., Deng, C., & Luo, Y. (2020) · Neuroreport · doi:10.1097/wnr.0000000000001466 · Cited by 33
Rhodamine-Based Metal Chelator: A Potent Inhibitor of Metal-Catalyzed Amyloid Toxicity
Pradhan, K., Das, G., Kar, C., Mukherjee, N., Khan, J., Mahata, T., Barman, S., & Ghosh, S. (2020) · ACS Omega · doi:10.1021/acsomega.0c02235 · Cited by 30
Asymptotic solutions of the Oosawa model for the length distribution of biofilaments
Michaels, T. C. T., Garcia, G. A., & Knowles, T. P. J. (2014) · The Journal of Chemical Physics · doi:10.1063/1.4875897 · Cited by 30
Mathew, A., Aravind, A., Brahatheeswaran, D., Fukuda, T., Nagaoka, Y., Hasumura, T., Iwai, S., Morimoto, H., Yoshida, Y., Maekawa, T., et al. (2012) · BioNanoScience · doi:10.1007/s12668-012-0040-y · Cited by 33
“existing ones [1, 4, 5].”
Lei, Y., Yang, L., Ye, C. Y., Qin, M. Y., Yang, H. Y., Jiang, H. L., Tang, X. C., & Zhang, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128366 · Cited by 33
“Compelling evidence shows that excessive accumulation of Aβ peptide in the brain is a central and perhaps defining event in the pathogenesis of AD [2, 3], thus “Aβ cascade hypothesis” is strongly supported by evidence of Aβ-related pathology and has been the focal point of research and pharmaceutical industry for the…”
Backgroundde Almeida, N. E. C., Do, T. D., Jhatro, M., LaPointe, N. E., Feinstein, S. C., Shea, J., & Bowers, M. T. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00280 · Cited by 32
Franchi, B., & Lorenzani, S. (2016) · Journal of Nonlinear Science · doi:10.1007/s00332-016-9288-7 · Cited by 30
“It is largely accepted that Aβ peptide (especially in soluble form) has a substantial role in the process of synaptic degeneration leading to neuronal death and eventually to dementia (the so-called amyloid cascade hypothesis [28]).”
BackgroundMelnyk, P., Vingtdeux, V., Burlet, S., Eddarkaoui, S., Grosjean, M., Larchanché, P.-E., Hochart, G., Sergheraert, C., Estrella, C., Barrier, M., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn5003013 · Cited by 35
“Conditioned medium was used to determine the secreted Aβ1–38, Aβ1–40 and Aβ1-42 concentrations, using the Human Aβ (1–40) and Aβ (1-38) Assay Kits (IBL) and the INNOTEST beta-Amyloid (1-42) ELISA Kit (Innogenetics).”
MethodInnate immunity in Alzheimer’s disease: the relevance of animal models?
Franco Bocanegra, D. K., Nicoll, J. A. R., & Boche, D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1729-4 · Cited by 30
“manner, and this has hampered the development of treatments for late-onset AD (Karran et al. 2011).”
BackgroundMethodInfluentialSaini, R. K., Shuaib, S., & Goyal, B. (2017) · Journal of Molecular Recognition · doi:10.1002/jmr.2656 · Cited by 30
“native conformation of Aβ42 or to destabilize the aggregation prone β‐ sheet conformation, and (3) and clearance of aggregates from the brain.(6)”
BackgroundAdsorption Mechanism of Amyloid Fibrils to Graphene Nanosheets and Their Structural Destruction
Zhang, N., Hu, X., Guan, P., Zeng, K., & Cheng, Y. (2018) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.8b09893 · Cited by 29
Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimer’s disease risk
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/258533 · Cited by 30
Gardner, L. E., White, J. D., Eimerbrink, M. J., Boehm, G. W., & Chumley, M. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.007 · Cited by 29
Rajkumar, M., Sakthivel, M., Senthilkumar, K., Thangaraj, R., & Kannan, S. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100100 · Cited by 29
“In addition, the predominant neurodegenerative characteristics gradually decreased in AD-induced rats (Shin et al., 2012; Karran et al., 2011).”
BackgroundLin, N., Gao, J., Mao, C., Sun, H., Lü, Q., & Cui, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.687053 · Cited by 37
Flavonoids and Alzheimer’s disease: reviewing the evidence for neuroprotective potential
Amin, M. A., Dehbia, Z., Nafady, M. H., Zehravi, M., Kumar, K. P., Haque, M. A., Baig, M. S., Farhana, A., Khan, S. L., Afroz, T., et al. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04922-w · Cited by 33
“These difficulties generate even more challenges for the Aβ theory [97].”
Bioenergetic failure and oxidative stress: mitochondrial contributions to Alzheimer’s disease
Wasim, R. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01916-6 · Cited by 33
“According to the amyloid cascade hypothesis, the development of amyloid plaques in the brain from the deposition of Aβ peptides is the first step in AD pathophysiology (Karran et al. 2011).”
Potential non-oncological applications of histone deacetylase inhibitors.
Ververis, K., & Karagiannis, T. C. (2011) · Europe PMC (PubMed Central) · Cited by 32
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 34
“org of amyloid from re-entering the brain, potentially shifting the amyloid gradient toward plaque dissolution and efflux out of the brain (29).”
BackgroundInfluentialSynaptic Protein Alterations in Parkinson’s Disease
Pienaar, I. S., Burn, D. J., Morris, C. M., & Dexter, D. T. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8226-9 · Cited by 32
“The Aβ cascade hypothesis, which states that Aβ accumulation is the principal pathological event leading to neurodegeneration in the AD brain [11], has received support from studies performed on transgenic mice that express familial mutations of human APP.”
BackgroundSimoni, E., Serafini, M. M., Bartolini, M., Caporaso, R., Pinto, A., Necchi, D., Fiori, J., Andrisano, V., Minarini, A., Lanni, C., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500422 · Cited by 30
Relationship Between Genetic Risk Factors and Markers for Alzheimer’s Disease Pathology
Elias-Sonnenschein, L. S., Bertram, L., & Visser, P. J. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.56 · Cited by 29
Branch, T., Barahona, M., Dodson, C. A., & Ying, L. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00121 · Cited by 31
Qin, X., Wang, Y., & Paudel, H. K. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.018 · Cited by 40
“59,60 Therefore, Egr-1 may promote tau phosphorylation via A b .”
BackgroundWang, M., Bi, W., Fan, K., Li, T., Yan, T., Xiao, F., He, B., Kai-shun, B., & Jia, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.088 · Cited by 29
“Past findings had shown that accumulation of abnormally folded Aβ and Tau proteins in amyloid plaques and neuronal tangles are causally related to neurodegenerative processes in patients' brains [2].”
BackgroundAβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
Jäkel, L., Boche, D., Nicoll, J. A. R., & Verbeek, M. M. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0791-6 · Cited by 33
Exploring the Role of P2X Receptors in Alzheimer’s Disease
Godoy, P. A., Ramírez-Molina, O., & Fuentealba, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01330 · Cited by 31
Nakamura, Y., Yamamoto, T., Xu, X., Kobayashi, S., Tanaka, S., Tamitani, M., Saito, T., Saido, T. C., & Yano, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-86822-x · Cited by 36
El-Ganainy, S. O., Gowayed, M. A., Agami, M. A., Mohamed, P., Belal, M., Farid, R. M., & Hanafy, A. S. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0051 · Cited by 29
A Novel Cu(II)-Binding Peptide Identified by Phage Display Inhibits Cu2+-Mediated Aβ Aggregation
Zhang, X., Zhang, X., Zhong, M., Zhao, P., Guo, C., Li, Y., Xu, H. J., Wang, T., & Gao, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136842 · Cited by 31
Moderating effect of cognitive reserve on brain integrity and cognitive performance
Nelson, M. E., Veal, B. M., Andel, R., Martínková, J., Veverová, K., Horáková, H., Nedelská, Z., Laczó, J., Vyhnálek, M., & Hort, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1018071 · Cited by 33
“According to the amyloid-cascade hypothesis (Hardy and Higgins, 1992; Karran et al., 2011; Jack and Holtzman, 2013; Jack et al., 2013), the temporal ordering of AD pathophysiology begins with amyloid-beta, followed by tau, and leading to eventual neurodegeneration.”
BackgroundKalita, S., Bergman, H., Dubey, K. D., & Shaik, S. S. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c12305 · Cited by 30
Cogswell, P. M., Lundt, E. S., Therneau, T. M., Mester, C. T., Wiste, H. J., Graff‐Radford, J., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Reid, R. I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38878-8 · Cited by 31
“These fi ndings support a strong mechanistic relationship of amyloid and tau, as anticipated based on priormodeling of AD biomarker progression and in keeping with the amyloid cascade hypothesis 27 – 29 .”
Alzheimer's Disease and Prion Protein
Zhou, J. (2013) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2013.v2.2.35 · Cited by 37
P7C3 Attenuates the Scopolamine-Induced Memory Impairments in C57BL/6J Mice
Jiang, B., Song, L., Huang, C., & Zhang, W. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1783-y · Cited by 30
“Characteristic neuropathological features of AD are accumulation of amyloid plaques, formation of neurofibrillary tangles, induction of oxidative stress and inflammatory responses, and disturbance in neurotransmission [3].”
Background
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.